{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"335.87","value":"60.06"},{"groupId":"OG001","spread":"109.88","value":"19.81"},{"groupId":"OG002","spread":"244.81","value":"9.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"339.27","value":"100.74"},{"groupId":"OG001","spread":"130.66","value":"23.09"},{"groupId":"OG002","spread":"379.81","value":"15.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Cycle 3 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"description":"Cmax is the maximum observed serum concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1/0.3/1/3/10 mg/kg every 2 weeks","id":"OG000","title":"Cohort 1 Uninfected HCC"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3/1/3 mg/kg every 2 weeks","id":"OG001","title":"Cohort 1 HCV Infected"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1/0.3/1/3 mg/kg every 2 weeks","id":"OG002","title":"Cohort 1 HBV Infected"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants in Cohort 1 with baseline and at least 1 post-baseline assessment; uninfected HCC, HCV-infected, and HBV-infected participants reported together as pre-specified.","reportingStatus":"POSTED","timeFrame":"At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)","title":"Maximum Observed Serum Concentration (Cmax)","type":"SECONDARY","unitOfMeasure":"ug/mL"}